Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 25	CA/CAPLUS - Russian Agency for Patents and Trademarks (ROSPATENT) added to list of core patent offices covered
NEWS	4	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	5	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	6	FEB 28	MEDLINE/LMEDLINE reloaded
NEWS	7	MAR 02	GBFULL: New full-text patent database on STN
NEWS	8	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	9	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	10	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	11	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	12	MAR 22	PATDPASPC - New patent database available
NEWS	13	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	14	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	15	APR 04	EMBASE - Database reloaded and enhanced

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:45:31 ON 08 APR 2005

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:45:38 ON 08 APR 2005

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 APR 2005 HIGHEST RN 848122-48-5
DICTIONARY FILE UPDATES: 7 APR 2005 HIGHEST RN 848122-48-5

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10661947.str



chain nodes :
6 14 15 16 17 18 19
ring nodes :
1 2 3 4 5 7 8 9 10 11 12
chain bonds :
2-14 3-6 5-17 6-7 17-18 18-19
ring bonds :
1-2 1-5 2-3 3-4 4-5 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
1-2 1-5 3-6 4-5 5-17 6-7 18-19

exact bonds :
2-3 2-14 3-4 17-18
normalized bonds :
7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS
20:CLASS 21:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 13:45:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 380 TO ITERATE

100.0% PROCESSED 380 ITERATIONS 8 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 6431 TO 8769
PROJECTED ANSWERS: 8 TO 329

L2 8 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 13:46:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 7767 TO ITERATE

100.0% PROCESSED 7767 ITERATIONS 203 ANSWERS
SEARCH TIME: 00.00.01

L3 203 SEA SSS FUL L1

=> s l3 and caplus/lc
45431149 CAPLUS/LC
L4 190 L3 AND CAPLUS/LC

=> s l3 not l4
L5 13 L3 NOT L4

=> d l5 1-13

L5 ANSWER 1 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN
RN 380425-94-5 REGISTRY
ED Entered STN: 04 Jan 2002
CN 1H-Pyrazole-1-ethanol, 4-(2-hydroxyphenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C13 H16 N2 O3
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 2 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN
RN 266362-64-5 REGISTRY
ED Entered STN: 24 May 2000
CN 1H-Pyrazole-1-acetamide, 3,5-dimethyl-N-[3-(methylthio)phenyl]-4-phenoxy- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H21 N3 O2 S
SR CAS Client Services
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 3 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN
RN 266362-63-4 REGISTRY
ED Entered STN: 24 May 2000
CN 1H-Pyrazole-1-acetamide, 3,5-dimethyl-4-phenoxy-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H18 F3 N3 O2
SR CAS Client Services



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 4 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN
RN 266362-62-3 REGISTRY
ED Entered STN: 24 May 2000
CN 1H-Pyrazole-1-acetamide, N-(3-chlorophenyl)-3,5-dimethyl-4-phenoxy- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H18 Cl N3 O2
SR CAS Client Services
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 5 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN
RN 266362-61-2 REGISTRY
ED Entered STN: 24 May 2000
CN 1H-Pyrazole-1-acetamide, 3,5-dimethyl-4-phenoxy-N-phenyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H19 N3 O2
SR CAS Client Services
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 6 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN
RN 264626-26-8 REGISTRY
ED Entered STN: 12 May 2000
CN 1H-Pyrazole-1-carboxamide, 4-(4-chlorophenoxy)-3,5-dimethyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C15 H18 Cl N3 O2
SR CAS Client Services
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 7 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN
RN 264626-25-7 REGISTRY
ED Entered STN: 12 May 2000
CN 1H-Pyrazole-1-carboxamide, 4-(4-chlorophenoxy)-3,5-dimethyl-N-phenyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H16 Cl N3 O2
SR CAS Client Services
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 8 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN
RN 264626-24-6 REGISTRY
ED Entered STN: 12 May 2000
CN 1H-Pyrazole-1-carboxamide, 3,5-dimethyl-N-(1-methylethyl)-4-phenoxy- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C15 H19 N3 O2
SR CAS Client Services



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 9 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN
RN 264626-23-5 REGISTRY
ED Entered STN: 12 May 2000
CN 1H-Pyrazole-1-carboxamide, 3,5-dimethyl-4-phenoxy-N-phenyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H17 N3 O2
SR CAS Client Services
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 10 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN
RN 264616-90-2 REGISTRY
ED Entered STN: 12 May 2000
CN 1H-Pyrazole, 1-benzoyl-3,5-dimethyl-4-phenoxy- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H16 N2 O2
SR CAS Client Services
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 11 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN
RN 264616-89-9 REGISTRY
ED Entered STN: 12 May 2000
CN 1H-Pyrazole, 4-(4-chlorophenoxy)-1-(cyclopropylcarbonyl)-3,5-dimethyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C15 H15 Cl N2 O2
SR CAS Client Services
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 12 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN
RN 264616-88-8 REGISTRY
ED Entered STN: 12 May 2000
CN 1H-Pyrazole, 1-benzoyl-4-(4-chlorophenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H15 Cl N2 O2
SR CAS Client Services
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 13 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN
RN 263767-20-0 REGISTRY
ED Entered STN: 04 May 2000
CN 1H-Pyrazole, 1-(4-chlorobenzoyl)-4-(4-chlorophenoxy)-3,5-dimethyl- (9CI)
(CA INDEX NAME)
FS 3D CONCORD
MF C18 H14 C12 N2 O2
SR CAS Client Services



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
=> fil caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                       190.71     190.92

FILE 'CAPLUS' ENTERED AT 13:47:22 ON 08 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 8 Apr 2005  VOL 142 ISS 16
FILE LAST UPDATED: 7 Apr 2005  (20050407/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> d his

     (FILE 'HOME' ENTERED AT 13:45:31 ON 08 APR 2005)

     FILE 'REGISTRY' ENTERED AT 13:45:38 ON 08 APR 2005
L1              STRUCTURE UPLOADED
L2            8 S L1
L3          203 S L1 FULL
L4          190 S L3 AND CAPLUS/LC
L5           13 S L3 NOT L4

     FILE 'CAPLUS' ENTERED AT 13:47:22 ON 08 APR 2005

=> s l4
L6          18 L4

=> d ibib abs hitstr l6 1-18
```

L6 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:308433 CAPLUS
DOCUMENT NUMBER: 140:321352
TITLE: Preparation of pyrazole derivatives as HIV reverse transcriptase inhibitors
INVENTOR(S): Price, David Anthony; Selby, Matthew Duncan; Stupple, Paul Anthony
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031178	A1	20040415	WO 2003-IB4205	20030924
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004133002	A1	20040708	US 2003-669819	20030923

PRIORITY APPLN. INFO.: GB 2002-23232 A 20021007
US 2002-432859P P 20021211

OTHER SOURCE(S): MARPAT 140:321352
GI



I



II

AB The title compds. [I; WXY = (un)substituted 5-6 membered partially saturated or aromatic ring containing 0-3 N atoms wherein X = CH or N and Y = CH or, when X = CH, may also be N; R1 = alkylene; R2 = H, alkyl, cycloalkyl, etc.; R3 = H, alkyl, cycloalkyl, Ph, etc.; R4 = (un)substituted Ph, naphthyl,

L6 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

pyridyl; n = 0-2] which bind to the enzyme reverse transcriptase and are modulators, esp. inhibitors thereof, and as such are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated, were prepd. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS). Thus, reacting 3-(5-aminomethyl-3-methyl-1H-pyrazol-4-yloxy)-5-chlorobenzonitrile (prepn. given) with Me 2-formylbenzoate in the presence of NaBH(OAc)3 and AcOH in CH2Cl2 afforded II which showed IC50 of 76 nM against HIV-1 reverse transcriptase. The pharmaceutical compn. comprising the compd. I is claimed.

IT **473923-70-5P 473923-73-8P 473924-23-1P**
678992-37-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazole derivs. as HIV reverse transcriptase inhibitors)

RN 473923-70-5 CAPLUS
CN 1H-Pyrazole, 1-acetyl-4-(3-chloro-5-cyanophenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 473923-73-8 CAPLUS
CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3-chloro-5-cyanophenoxy)-5-methyl- (9CI) (CA INDEX NAME)



RN 473924-23-1 CAPLUS
CN 1H-Pyrazole, 1-acetyl-4-(3,5-dicyanophenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)

L6 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 678992-37-5 CAPLUS
CN 1H-Pyrazole, 1-acetyl-5-(bromomethyl)-4-(3,5-dicyanophenoxy)-3-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:292024 CAPLUS
DOCUMENT NUMBER: 140:303665
TITLE: Preparation of pyrazole amides for treating HIV infections
INVENTOR(S): Jones, Lyn Howard; Mowbray, Charles Eric; Price, David Anthony; Selby, Matthew Duncan; Stupple, Paul Anthony
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004029051	A1	20040408	WO 2003-IB4071	20030915
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005004129	A1	20050106	US 2003-669794	20030923

PRIORITY APPLN. INFO.: GB 2002-22375 A 20020926
GB 2002-23357 A 20021008
US 2002-433220P P 20021213

OTHER SOURCE(S): MARPAT 140:303665
GI



I



II

AB The title compds. [I; WXY = (un)substituted 5-6 membered partially saturated or aromatic ring containing 0-3 N atoms wherein X = CH or N and Y = CH, or, when X = CH, may also be N; R1 = a bond, alkylene, R2 = H, alkyl, cycloalkyl, etc.; R3 = H, alkyl, cycloalkyl, etc.; R4 = (un)substituted Ph, naphthyl, pyridyl; n = 0-2] which bind to the enzyme reverse transcriptase and are

L6 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

modulators, esp. inhibitors thereof, were prepd. and formulated. Thus, reacting [4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]acetic acid (prepn. given) with 5,6,7,8-tetrahydro-[1,6]naphthyridine afforded II. The compds. I were tested for inhibition of HIV-1 reverse transcriptase enzyme (data were given for representative compds. I). The compds. I are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).

IT **473923-49-8P 473923-52-3P 473923-70-5P**
473923-73-8P 676994-56-2P 676994-57-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazole amides for treating HIV infections)

RN 473923-49-8 CAPLUS
CN 1H-Pyrazole, 1-acetyl-4-(3,5-dichlorophenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 473923-52-3 CAPLUS
CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3,5-dichlorophenoxy)-5-methyl- (9CI) (CA INDEX NAME)



RN 473923-70-5 CAPLUS
CN 1H-Pyrazole, 1-acetyl-4-(3-chloro-5-cyanophenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)

L6 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 473923-73-8 CAPLUS
CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3-chloro-5-cyanophenoxy)-5-methyl- (9CI) (CA INDEX NAME)



RN 676994-56-2 CAPLUS
CN 1H-Pyrazole, 4-(3,5-dicyanophenoxy)-1-(2,2-dimethyl-1-oxopropyl)-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 676994-57-3 CAPLUS
CN 1H-Pyrazole, 5-(bromomethyl)-4-(3,5-dicyanophenoxy)-1-(2,2-dimethyl-1-oxopropyl)-3-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:287840 CAPLUS
DOCUMENT NUMBER: 140:303663
TITLE: Preparation of pyrazole derivatives as reverse transcriptase inhibitors
INVENTOR(S): Barba, Oscar; Jones, Lyn Howard
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004029042	A1	20040408	WO 2003-IB4158	20030915
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004110816	A1	20040610	US 2003-669812	20030923
PRIORITY APPLN. INFO.:			GB 2002-22374 A	20020926
			GB 2002-23356 A	20021008
			US 2002-433402P P	20021213
OTHER SOURCE(S):	MARPAT 140:303663			

GI



I

AB The title compds. [I; R1 = (un)substituted 5-6 membered heteroaryl containing
(1) 1-4 N atoms or (2) 1-2 N atoms and 1 O atom or 1 S atom or (3) 1 or 2 O or S atoms; R2 = H, alkyl, cycloalkyl, etc.; R3 = H, alkyl, cycloalkyl, etc.; R4 = (un)substituted Ph, naphthyl, pyridyl] which bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof, were
prepared and formulated. Thus, reacting 5-(3-ethyl-1-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-yloxy)isophthalonitrile (preparation given) with 2-chloropyridine afforded I [R1 = 2-pyridyl; R2 = Me; R3 = Et; R4 = 3,5-dicyanophenyl] which showed IC50 of 5400 nM against HIV-1 reverse transcriptase. The compds. I are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human

Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).

IT **676995-20-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazole derivs. as reverse transcriptase inhibitors)

RN 676995-20-3 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3-ethyl-1-(2-hydroxyethyl)-5-(2-pyridinyloxy)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



IT **676995-24-7P 676995-26-9P 676995-27-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazole derivs. as reverse transcriptase inhibitors)

RN 676995-24-7 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3-ethyl-4,5-dihydro-1-(2-hydroxyethyl)-5-oxo-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 676995-26-9 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3-ethyl-4,5-dihydro-5-oxo-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 676995-27-0 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3-ethyl-5-(2-pyridinyloxy)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2004:253142 CAPLUS
DOCUMENT NUMBER: 140:287377
TITLE: Preparation of pyrazolyloxyisophthalonitrile as reverse transcriptase inhibitor in the treatment of AIDS
INVENTOR(S): Mowbary, Charles Eric; Price, David Anthony; Selby, Matthew Duncan; Stupple, Paul Anthony
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004024147	A1	20040325	WO 2003-IB3946	20030908
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004132793	A1	20040708	US 2003-661947	20030912
PRIORITY APPLN. INFO.:			GB 2002-21477 A	20020916
			GB 2002-23354 A	20021008
			US 2002-433397P P	20021213

GI



I

AB This invention relates to 5-[[3-cyclopropyl-1-(2-hydroxyethyl)-5-methyl-1H-pyrazol-4-yl]oxy]isophthalonitrile (shown as I) and pharmaceutically acceptable salt, solvate or derivs. thereof, to their use in medicine, to compns. containing them, to processes for their preparation and to intermediates used in such processes. I binds to the enzyme reverse transcriptase (IC50 = 295 nM) and is an inhibitor thereof. I had t1/2 >120 min in human liver microsomes and Supermix; it had an unbound hepatocyte clearance <9 mL/min/kg in human hepatocytes. Reverse transcriptase is implicated in the infectious life cycle of Human Immunodeficiency Virus (HIV). Compds. which interfere with the function of this enzyme showed utility in the treatment of conditions caused by HIV and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS) (no

data). Two examples of the prepn. of I are given: cyclocondensation of 2-hydroxyethylhydrazine with 5-[1-(cyclopropylcarbonyl)-2-oxopropoxy]isophthalonitrile (and sepn. of regioisomers) and deprotection of 5-[[3-cyclopropyl-5-methyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl]oxy]isophthalonitrile; prepn. of the reactants is described.

IT **675198-29-5P**, 5-[[3-Cyclopropyl-1-(2-hydroxyethyl)-5-methyl-1H-pyrazol-4-yl]oxy]isophthalonitrile
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrazolyloxyisophthalonitrile as reverse transcriptase inhibitor in treatment of AIDS)

RN 675198-29-5 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3-cyclopropyl-1-(2-hydroxyethyl)-5-methyl-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



IT **675198-33-1P**, 5-[[3-Cyclopropyl-5-methyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl]oxy]isophthalonitrile
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolyloxyisophthalonitrile as reverse transcriptase inhibitor in treatment of AIDS)

RN 675198-33-1 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3-cyclopropyl-5-methyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



IT **675198-30-8P**, 5-[[5-Cyclopropyl-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-yl]oxy]isophthalonitrile **675198-34-2P**, 5-[[5-Cyclopropyl-3-methyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl]oxy]isophthalonitrile

L6 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of pyrazolyloxyisophthalonitrile as reverse transcriptase inhibitor in treatment of AIDS)
RN 675198-30-8 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[5-cyclopropyl-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 675198-34-2 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[5-cyclopropyl-3-methyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:174482 CAPLUS
DOCUMENT NUMBER: 138:198678
TITLE: Small-molecule modulators of hepatocyte growth factor/scatter factor activities as drugs
INVENTOR(S): Pillarisetti, Sivaram; Goldberg, Itzhak D.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 37 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003045559	A1	20030306	US 2001-896832	20010629
US 6589997	B2	20030708		
US 2003022924	A1	20030130	US 2001-26672	20011219
US 6610726	B2	20030826		
US 2003216459	A1	20031120	US 2003-456326	20030606
US 6855728	B2	20050215		
PRIORITY APPLN. INFO.:			US 2001-896832	A2 20010629
OTHER SOURCE(S):		MARPAT 138:198678		

AB The invention is directed to small organic mols. having the ability to mimic or agonize hepatocyte growth factor/scatter factor (HGF/SF) activity, or inhibit or antagonize HGF/SF activity, the former useful for promoting, for example, vascularization of tissues or organs for promoting wound or tissue healing, or augmenting or restoring blood flow to ischemic tissues such as the heart following myocardial infarction. Inhibition of cellular growth or proliferation is beneficial in the treatment, for example, of inflammatory diseases such as inflammatory joint and skin diseases, and dysproliferative diseases such as cancer. Pharmaceutical compns. containing the modulators are also claimed.
IT 264616-91-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(small-mol. modulators of hepatocyte growth factor/scatter factor activities as drugs)
RN 264616-91-3 CAPLUS
CN 1H-Pyrazole, 1-(4-chlorobenzoyl)-3,5-dimethyl-4-phenoxy- (9CI) (CA INDEX NAME)



L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:832763 CAPLUS
DOCUMENT NUMBER: 137:337884
TITLE: Preparation of aryloxy pyrazole derivatives as reverse transcriptase inhibitors for treating HIV
INVENTOR(S): Jones, Lyn Howard; Mowbray, Charles Eric; Price, Davis Anthony; Selby, Matthew Duncan; Stupple, Paul Anthony
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 306 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085860	A1	20021031	WO 2002-IB1234	20020404
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2443449	AA	20021031	CA 2002-2443449	20020404
EP 1377556	A1	20040107	EP 2002-708600	20020404
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300497	A	20040216	EE 2003-497	20020404
BR 2002008811	A	20040309	BR 2002-8811	20020404
JP 2004531535	T2	20041014	JP 2002-583387	20020404
US 2003100554	A1	20030529	US 2002-118512	20020405
ZA 2003007095	A	20040910	ZA 2003-7095	20030910
NO 2003004523	A	20031209	NO 2003-4523	20031009
PRIORITY APPLN. INFO.:			GB 2001-8999	A 20010410
			GB 2001-27426	A 20011115
			US 2001-289570P	P 20010508
			US 2002-346727P	P 20020107
			WO 2002-IB1234	W 20020404
OTHER SOURCE(S):		MARPAT 137:337884		

GI



AB This invention relates to pyrazole derivs. (shown as I; e.g. 2-Amino-6-[[4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]methyl]-

L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
4(3H)-pyrimidinone) or pharmaceutically acceptable salts, solvates or deriv. thereof, wherein R1 to R4 are defined below, and to processes for the prepn. thereof, intermediates used in their prepn. of, compns. contg. them and the uses of such derivs. The compds. of the present invention bind to the enzyme reverse transcriptase and are modulators, esp. inhibitors thereof. As such the compds. of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodeficiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS). In tests of inhibition of HIV-1 reverse transcriptase enzyme, the claimed compds. 2-amino-6-[[4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]methyl]-4(3H)-pyrimidinone, 3,5-dimethyl-4-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile and 1-(3-azetidinyl)-4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazole had IC50 values of 39,000, 3,200 and 248 nM, resp. In I: R1 is H, C1-C6 alkyl, C3-C7 cycloalkyl, Ph, benzyl, halo, -CN, -OR7, -CO2R10, -CONR5R10, R8 or R9. R2 is H, C1-C6 alkyl, C3-C6 alkenyl, C3-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, Ph, benzyl, R8 or R9; or, R1 and R2, when taken together, represent unbranched C3-C4 alkylene. R3 is H, C1-C6 alkyl, C3-C7 cycloalkyl, Ph, benzyl, halo, -CN, -OR7, -CO2R5, -CONR5R5, R8 or R9; R4 is Ph, naphthyl or pyridyl. Definitions of R5 and R7-R10 and addnl. specifications are given in the claims. Included are 283 claimed-compd. prepns. and 115 intermediate prepns.
IT 473919-45-8P, 2-[4-(3,5-Dichlorophenoxy)-3,5-dimethyl-1H-pyrazol-1-yl]ethanol 473919-54-9P, Methyl [4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetate 473919-56-1P, 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetohydrazide 473919-83-4P, 2-[4-(3,5-Difluorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol 473920-32-0P, Ethyl [4-(3-cyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetate 473920-89-7P, 5-[[1-(2-Hydroxyethyl)-3-isopropyl-5-methyl-1H-pyrazol-4-yl]oxy]isophthalonitrile 473921-04-9P, 3-Chloro-5-[[1-(2-hydroxyethyl)-3,5-dimethyl-1H-pyrazol-4-yl]oxy]benzonitrile 473921-10-7P, 3-Fluoro-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473921-11-8P, 3-Methyl-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473921-12-9P, 3-Cyano-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473921-50-5P, 5-[[3-tert-Butyl-1-(2-hydroxyethyl)-5-methyl-1H-pyrazol-4-yl]oxy]isophthalonitrile 473921-56-1P, 3-(1H-Pyrazol-1-yl)-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473921-60-7P, 3-[[3,5-Diethyl-1-(2-hydroxyethyl]-1H-pyrazol-4-yl]oxy]-5-fluorobenzamide 473921-63-0P, 5-[[5-Ethyl-1-(2-hydroxyethyl)-3-isopropyl-1H-pyrazol-4-yl]oxy]isophthalonitrile 473921-73-2P, 5-[[3,5-Diethyl-1-((methoxycarbonyl)methyl)-1H-pyrazol-4-yl]oxy]-1,3-benzenedicarbonitrile 473921-85-6P, 3-[[3-Cyclopropyl-1-(2-hydroxyethyl)-5-methyl-1H-pyrazol-4-yl]oxy]-5-methylbenzonitrile 473921-96-9P, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-methoxybenzonitrile 473922-65-5P, 3-[[3,5-Diethyl-1-(2-hydroxyethyl]-1H-pyrazol-4-yl]oxy]-5-(methylsulfanyl)benzonitrile 473922-87-1P, 5-[[3,5-Diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl]oxy]isophthalonitrile 473923-08-9P, Di(tert-butyl) 2-[4-(3,5-dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl phosphate
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of aryloxy pyrazole derivs. as reverse transcriptase inhibitors for treating HIV)

L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 473919-45-8 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(3,5-dichlorophenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 473919-54-9 CAPLUS
CN 1H-Pyrazole-1-acetic acid, 4-(3,5-dichlorophenoxy)-3,5-diethyl-, methyl ester (9CI) (CA INDEX NAME)



RN 473919-56-1 CAPLUS
CN 1H-Pyrazole-1-acetic acid, 4-(3,5-dichlorophenoxy)-3,5-diethyl-, hydrazide (9CI) (CA INDEX NAME)

L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 473919-83-4 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(3,5-difluorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473920-32-0 CAPLUS
CN 1H-Pyrazole-1-acetic acid, 4-(3-cyanophenoxy)-3,5-diethyl-, ethyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 473920-89-7 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[1-(2-hydroxyethyl)-5-methyl-3-(1-methylethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-04-9 CAPLUS
CN Benzonitrile, 3-chloro-5-[[1-(2-hydroxyethyl)-3,5-dimethyl-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-10-7 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-fluoro- (9CI) (CA INDEX NAME)



L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 473921-11-8 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-methyl- (9CI) (CA INDEX NAME)



RN 473921-12-9 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-50-5 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3-(1,1-dimethylethyl)-1-(2-hydroxyethyl)-5-methyl-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-56-1 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 473921-60-7 CAPLUS
CN Benzamide, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-fluoro- (9CI) (CA INDEX NAME)



RN 473921-63-0 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[5-ethyl-1-(2-hydroxyethyl)-3-(1-methylethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-73-2 CAPLUS
CN 1H-Pyrazole-1-acetic acid, 4-(3,5-dicyanophenoxy)-3,5-diethyl-, methyl ester (9CI) (CA INDEX NAME)

CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(methylthio)- (9CI) (CA INDEX NAME)



RN 473922-87-1 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473923-08-9 CAPLUS
CN Phosphoric acid, 2-[4-(3,5-dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)





RN 473921-85-6 CAPLUS
CN Benzonitrile, 3-[[3-cyclopropyl-1-(2-hydroxyethyl)-5-methyl-1H-pyrazol-4-yl]oxy]-5-methyl- (9CI) (CA INDEX NAME)



RN 473921-96-9 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-methoxy- (9CI) (CA INDEX NAME)



RN 473922-65-5 CAPLUS

IT **473919-46-9P**, 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-55-0P**, 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetamide **473919-62-9P**, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473919-65-2P**, 2-[4-(2,6-Dimethyl-4-cyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-66-3P**, 2-[4-(2-Chloro-4-cyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-67-4P**, 2-[4-(4-Fluoro-3-cyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-68-5P**, 2-[4-(4-Chlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-69-6P**, 2-[4-(3-Chlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-70-9P**, 2-[4-(2-Chlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-71-0P**, 2-[4-(2,6-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-72-1P**, 2-[4-(2,3-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-73-2P**, 2-[4-(2,4-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-74-3P**, 2-[3,5-Diethyl-4-(2-fluorophenoxy)-1H-pyrazol-1-yl]ethanol **473919-75-4P**, 2-[3,5-Diethyl-4-(3-fluorophenoxy)-1H-pyrazol-1-yl]ethanol **473919-76-5P**, 2-[4-(3,5-Dimethylphenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-77-6P**, 2-[4-(3-Methyl-4-fluorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-78-7P**, 2-[4-(2,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-79-8P**, 2-[4-(2,3-Difluorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-80-1P**, 2-[4-(3,4-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-81-2P**, 2-[4-(2,6-Difluorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-82-3P**, 2-[4-(2,5-Difluorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol **473919-84-5P**, 4-(3,5-Dichlorophenoxy)-3,5-diethyl-1-(2-methoxyethyl)-1H-pyrazole **473919-86-7P**, 4-(3,5-Dichlorophenoxy)-3,5-diethyl-1-(methoxymethyl)-1H-pyrazole **473920-14-8P**, 1-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]-2-propanol **473920-16-0P**, 2-[2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethoxy]ethanamine **473920-21-7P**, 2-[4-(3,5-Dichlorophenoxy)-3-ethyl-5-methoxy-1H-pyrazol-1-yl]ethanol **473920-29-5P**, 2-[4-(3-Cyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetamide **473920-87-5P**, 2-[4-(3,5-Dichlorophenoxy)-3-methyl-5-[[[(3-pyridinyl)methyl]amino]methyl]-1H-pyrazol-1-yl]ethanol **473921-05-0P**, 3-Chloro-5-[[5-[[(4-cyanobenzyl)amino]methyl]-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-yl]oxy]benzonitrile **473921-13-0P**, 3-Chloro-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473921-39-0P**, 3-[[3,5-Diethyl-1-(2-methoxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473921-48-1P**, 3-[[5-(Aminomethyl)-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-yl]oxy]-5-chlorobenzonitrile **473921-52-7P**, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(1H-1,2,4-triazol-1-yl)benzonitrile **473921-53-8P**, 3-(1,4-Dihydro-4-oxo-1-pyridyl)-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473921-54-9P**, 3-(1H-1,2,3-Triazol-1-yl)-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473921-55-0P**, 3-(2H-1,2,3-Triazol-2-yl)-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473921-57-2P**, 3-(1,2-Dihydro-2-oxo-1-pyridyl)-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473921-58-3P**, 3-(2,3-Dihydro-3-oxo-1,2-diazin-2-yl)-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473921-59-4P**, 3-(2,5-Dihydro-2,3-dimethyl-5-oxo-1H-pyrazol-1-yl)-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile **473921-61-8P**, 5-[[3-Cyclopropyl-5-ethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile **473921-62-9P**, 5-[[5-Cyclopropyl-3-ethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile

L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
473921-64-1P, 5-[[3-Ethyl-1-(2-hydroxyethyl)-5-isopropyl-1H-pyrazol-4-yl]oxy]isophthalonitrile 473921-65-2P, 2-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl carbamate 473921-69-6P, 5-[[3,5-Diethyl-1-(3-hydroxypropyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile 473921-71-0P, 5-[[3,5-Diethyl-1-(2-methoxyethyl)-1H-pyrazol-4-yl]oxy]-1,3-benzenedicarbonitrile 473921-74-3P, 2-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetamide 473921-75-4P, 5-[[3,5-Diethyl-1-(hydroxymethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile 473921-83-4P, 5-[[3,5-Dicyclopropyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile 473921-86-7P, 3-[[5-Cyclopropyl-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-yl]oxy]-5-methylbenzonitrile 473921-91-4P, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-4-methoxybenzonitrile 473921-92-5P 473921-93-6P 473921-94-7P, 2-[4-[3,5-Bis(1H-pyrazol-1-yl)phenoxy]-3,5-diethyl-1H-pyrazol-1-yl]ethanol 473921-95-8P, 2-[3,5-Diethyl-4-[3-fluoro-5-(1H-pyrazol-1-yl)phenoxy]-1H-pyrazol-1-yl]ethanol 473922-01-9P, 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]-N-[(2-pyridinyl)methyl]acetamide 473922-67-7P, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(methylsulfinyl)benzonitrile 473922-70-2P, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(methylsulfonyl)benzonitrile 473922-73-5P, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-[2-(dimethylamino)ethoxy]benzonitrile 473922-74-6P, 3-(2-(Methylamino)ethoxy)-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473922-77-9P, 3-((Aminocarbonyl)methoxy)-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473922-79-1P, 3-(2-Methoxyethoxy)-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473922-85-9P, 3-Fluoro-5-[[1-(2-hydroxyethyl)-5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473922-89-3P, 3-Cyano-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzamide 473922-93-9P, 5-[[5-Ethyl-3-(1-hydroxyethyl)-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile 473922-94-0P, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(5-trifluoromethyl-1,2,4-oxadiazol-3-yl)benzonitrile 473922-96-2P, 3-(5-Methyl-1,2,4-oxadiazol-3-yl)-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473922-98-4P, 3-(5-Ethyl-1,2,4-oxadiazol-3-yl)-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473922-99-5P, 3-(5-Isopropyl-1,2,4-oxadiazol-3-yl)-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473923-11-4P, 2-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl dihydrogen phosphate 473923-14-7P, 5-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile monosulfate 473923-17-0P, 5-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile mono(benzenesulfonate) 473923-20-5P, 5-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile monotosylate 473923-24-9P, 5-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile monomesylate 473924-71-9P, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(1H-pyrazol-1-yl)benzamide 473924-72-0P, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(2-oxo-1(2H)-pyridinyl)benzamide 473924-73-1P, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(6-oxo-1(6H)-pyridazinyl)benzamide 473924-74-2P, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(2,3-dimethyl-5-oxo-2,5-dihydro-1H-pyrazol-1-yl)benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of aryloxy pyrazole derivs. as reverse

L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 473919-65-2 CAPLUS
CN Benzonitrile, 4-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 473919-66-3 CAPLUS
CN Benzonitrile, 3-chloro-4-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473919-67-4 CAPLUS
CN Benzonitrile, 5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-2-

L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
transcriptase inhibitors for treating HIV)

RN 473919-46-9 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(3,5-dichlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473919-55-0 CAPLUS
CN 1H-Pyrazole-1-acetamide, 4-(3,5-dichlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473919-62-9 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)

L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
fluoro- (9CI) (CA INDEX NAME)



RN 473919-68-5 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(4-chlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473919-69-6 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(3-chlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 473919-70-9 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(2-chlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473919-71-0 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(2,6-dichlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473919-72-1 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(2,3-dichlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473919-73-2 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(2,4-dichlorophenoxy)-3,5-diethyl- (9CI) (CA

L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
INDEX NAME)



RN 473919-77-6 CAPLUS
CN 1H-Pyrazole-1-ethanol, 3,5-diethyl-4-(4-fluoro-3-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 473919-78-7 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(2,5-dichlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473919-79-8 CAPLUS

L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
INDEX NAME)



RN 473919-74-3 CAPLUS
CN 1H-Pyrazole-1-ethanol, 3,5-diethyl-4-(2-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 473919-75-4 CAPLUS
CN 1H-Pyrazole-1-ethanol, 3,5-diethyl-4-(3-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 473919-76-5 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(3,5-dimethylphenoxy)-3,5-diethyl- (9CI) (CA

L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Pyrazole-1-ethanol, 4-(2,3-difluorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473919-80-1 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(3,4-dichlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473919-81-2 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(2,6-difluorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473919-82-3 CAPLUS

CN 1H-Pyrazole-1-ethanol, 4-(2,5-difluorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473919-84-5 CAPLUS

CN 1H-Pyrazole, 4-(3,5-dichlorophenoxy)-3,5-diethyl-1-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 473919-86-7 CAPLUS

CN 1H-Pyrazole, 4-(3,5-dichlorophenoxy)-3,5-diethyl-1-(methoxymethyl)- (9CI) (CA INDEX NAME)



RN 473920-14-8 CAPLUS

RN 473920-29-5 CAPLUS

CN 1H-Pyrazole-1-acetamide, 4-(3-cyanophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473920-87-5 CAPLUS

CN 1H-Pyrazole-1-ethanol, 4-(3,5-dichlorophenoxy)-3-methyl-5-[[(3-pyridinylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 473921-05-0 CAPLUS

CN Benzonitrile, 3-chloro-5-[[5-[[[(4-cyanophenyl)methyl]amino]methyl]-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)

CN 1H-Pyrazole-1-ethanol, 4-(3,5-dichlorophenoxy)-3,5-diethyl-α-methyl- (9CI) (CA INDEX NAME)



RN 473920-16-0 CAPLUS

CN Ethanamine, 2-[2-[4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethoxy]- (9CI) (CA INDEX NAME)



RN 473920-21-7 CAPLUS

CN 1H-Pyrazole-1-ethanol, 4-(3,5-dichlorophenoxy)-3-ethyl-5-methoxy- (9CI) (CA INDEX NAME)





RN 473921-13-0 CAPLUS

CN Benzonitrile, 3-chloro-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-39-0 CAPLUS

CN Benzonitrile, 3-[[3,5-diethyl-1-(2-methoxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-48-1 CAPLUS

L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Benzonitrile, 3-[[5-(aminomethyl)-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-yl]oxy]-5-chloro- (9CI) (CA INDEX NAME)



RN 473921-52-7 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(1H-1,2,4-triazol-1-yl)- (9CI) (CA INDEX NAME)



RN 473921-53-8 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(4-oxo-1(4H)-pyridinyl)- (9CI) (CA INDEX NAME)



RN 473921-54-9 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(1H-1,2,3-triazol-1-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 473921-55-0 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(2H-1,2,3-triazol-2-yl)- (9CI) (CA INDEX NAME)



RN 473921-57-2 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(2-oxo-1(2H)-pyridinyl)- (9CI) (CA INDEX NAME)



RN 473921-58-3 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(6-oxo-1(6H)-pyridazinyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 473921-59-4 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(2,5-dihydro-2,3-dimethyl-5-oxo-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 473921-61-8 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3-cyclopropyl-5-ethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-62-9 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[5-cyclopropyl-3-ethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)

L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 473921-64-1 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3-ethyl-1-(2-hydroxyethyl)-5-(1-methylethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-65-2 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[1-[2-[(aminocarbonyl)oxy]ethyl]-3,5-diethyl-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-69-6 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-diethyl-1-(3-hydroxypropyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-71-0 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-diethyl-1-(2-methoxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-74-3 CAPLUS
CN 1H-Pyrazole-1-acetamide, 4-(3,5-dicyanophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473921-75-4 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-diethyl-1-(hydroxymethyl)-1H-pyrazol-4-



RN 473921-92-5 CAPLUS
CN 1H-Pyrazole-1-ethanol, 3,5-diethyl-4-(1-naphthalenyloxy)- (9CI) (CA INDEX NAME)



RN 473921-93-6 CAPLUS
CN 1H-Pyrazole-1-ethanol, 3,5-diethyl-4-(2-naphthalenyloxy)- (9CI) (CA INDEX NAME)



RN 473921-94-7 CAPLUS
CN 1H-Pyrazole-1-ethanol, 4-(3,5-di-1H-pyrazol-1-ylphenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)

yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-83-4 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-dicyclopropyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473921-86-7 CAPLUS
CN Benzonitrile, 3-[[5-cyclopropyl-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-yl]oxy]-5-methyl- (9CI) (CA INDEX NAME)



RN 473921-91-4 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 473921-95-8 CAPLUS
CN 1H-Pyrazole-1-ethanol, 3,5-diethyl-4-[3-fluoro-5-(1H-pyrazol-1-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 473922-01-9 CAPLUS
CN 1H-Pyrazole-1-acetamide, 4-(3,5-dichlorophenoxy)-3,5-diethyl-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 473922-67-7 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(methylsulfinyl)- (9CI) (CA INDEX NAME)



RN 473922-70-2 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 473922-73-5 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-[2-(dimethylamino)ethoxy]- (9CI) (CA INDEX NAME)





RN 473922-85-9 CAPLUS
CN Benzonitrile, 3-fluoro-5-[[1-(2-hydroxyethyl)-5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473922-89-3 CAPLUS
CN Benzamide, 3-cyano-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473922-93-9 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[5-ethyl-3-(1-hydroxyethyl)-1-(2-

RN 473922-74-6 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-[2-(methylamino)ethoxy]- (9CI) (CA INDEX NAME)



RN 473922-77-9 CAPLUS
CN Acetamide, 2-[3-cyano-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 473922-79-1 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)

hydroxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473922-94-0 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



RN 473922-96-2 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(5-methyl-1,2,4-oxadiazol-3-yl)- (9CI) (CA INDEX NAME)



RN 473922-98-4 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(5-ethyl-1,2,4-oxadiazol-3-yl)- (9CI) (CA INDEX NAME)



RN 473922-99-5 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



RN 473923-11-4 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-diethyl-1-[2-(phosphonooxy)ethyl]-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473923-14-7 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-, sulfate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 473921-12-9
CMF C17 H18 N4 O2



RN 473923-20-5 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-, mono(4-methylbenzenesulfonate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 473921-12-9
CMF C17 H18 N4 O2



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 473923-24-9 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-, monomethanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 473921-12-9
CMF C17 H18 N4 O2



CM 2

CRN 7664-93-9
CMF H2 O4 S

RN 473923-17-0 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-, monobenzenesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 473921-12-9
CMF C17 H18 N4 O2



CM 2

CRN 98-11-3
CMF C6 H6 O3 S



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 473924-71-9 CAPLUS
CN Benzamide, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 473924-72-0 CAPLUS
CN Benzamide, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(2-oxo-1(2H)-pyridinyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 473924-73-1 CAPLUS
CN Benzamide, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(6-oxo-1(6H)-pyridazinyl)- (9CI) (CA INDEX NAME)



RN 473924-74-2 CAPLUS
CN Benzamide, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(2,5-dihydro-2,3-dimethyl-5-oxo-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



IT 473923-41-0P, Ethyl 4-[4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]-3-oxobutanoate 473923-43-2P, {4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl}acetic acid

L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(methylsulfanyl)benzonitrile 473924-43-5P, 3-[[3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-[2-(dimethylamino)ethoxy]benzonitrile 473924-44-6P, 3-[[3,5-Diethyl-1-[2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-(2-(methylamino)ethoxy)benzonitrile 473924-45-7P, 3-[[3,5-Diethyl-1-[2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-((aminocarbonyl)methoxy)benzonitrile 473924-46-8P, 3-[[3,5-Diethyl-1-[2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-(2-methoxyethoxy)benzonitrile 473924-48-0P, 3-Fluoro-5-[[5-methyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-3-(trifluoromethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473924-49-1P, 3-Cyano-5-[[3,5-diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl]oxy]benzamide 473924-50-4P, 5-[(1-Acetyl-3,5-diethyl-1H-pyrazol-4-yl)oxy]isophthalonitrile 473924-51-5P, 5-[[1-Acetyl-3-(1-bromoethyl)-5-ethyl-1H-pyrazol-4-yl]oxy]isophthalonitrile 473924-52-6P, 5-[[5-Ethyl-3-(1-hydroxyethyl)-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl]oxy]isophthalonitrile 473924-53-7P, 3-Cyano-5-[[3,5-diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl]oxy]-N'-hydroxybenzenecarboximidamide 473924-54-8P, 3-[[3,5-Diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzonitrile 473924-55-9P, 3-[[3,5-Diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-[5-methyl-1,2,4-oxadiazol-3-yl]benzonitrile 473924-56-0P, 3-[[3,5-Diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-[5-ethyl-1,2,4-oxadiazol-3-yl]benzonitrile 473924-57-1P, 3-[[3,5-Diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-[5-isopropyl-1,2,4-oxadiazol-3-yl]benzonitrile
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of aryloxy pyrazole derivs. as reverse transcriptase inhibitors for treating HIV)
RN 473923-41-0 CAPLUS
CN 1H-Pyrazole-1-butanoic acid, 4-(3,5-dichlorophenoxy)-3,5-diethyl-β-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 473923-43-2 CAPLUS
CN 1H-Pyrazole-1-acetic acid, 4-(3,5-dichlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)

L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
473923-49-8P, 1-Acetyl-4-(3,5-dichlorophenoxy)-3,5-dimethyl-1H-pyrazole 473923-52-3P, 1-Acetyl-3-(bromomethyl)-4-(3,5-dichlorophenoxy)-5-methyl-1H-pyrazole 473923-61-4P, 4-(3,5-Dichlorophenoxy)-5-ethyl-2-(2-hydroxyethyl)-2,4-dihydro-3H-pyrazol-3-one 473923-63-6P, 2-[2-[(tert-Butyldimethylsilyl)oxy]ethyl]-4-(3,5-dichlorophenoxy)-5-ethyl-2,4-dihydro-3H-pyrazol-3-one 473923-65-8P, 1-[2-[(tert-Butyldimethylsilyl)oxy]ethyl]-4-(3,5-dichlorophenoxy)-3-ethyl-1H-pyrazol-5-yl trifluoromethanesulfonate 473923-70-5P, 3-[(1-Acetyl-3,5-dimethyl-1H-pyrazol-4-yl)oxy]-5-chlorobenzonitrile 473923-73-8P, 3-[(1-Acetyl-3-(bromomethyl)-5-methyl-1H-pyrazol-4-yl)oxy]-5-chlorobenzonitrile 473923-77-2P, N-[[1-[2-[(tert-Butyldimethylsilyl)oxy]ethyl]-4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl]-N-[(3-pyridinyl)methyl]amine 473923-85-2P, 5-[[1-[2-[[tert-Butyldimethylsilyl]oxy]ethyl]-3-isopropyl-5-methyl-1H-pyrazol-4-yl]oxy]isophthalonitrile 473923-89-6P, 1-[2-[(tert-Butyldimethylsilyl)oxy]ethyl]-4-(3,5-dichlorophenoxy)-3,5-dimethyl-1H-pyrazole 473923-91-0P, 5-(Bromomethyl)-1-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazole 473923-92-1P, 3-[[1-[2-[(tert-Butyldimethylsilyl)oxy]ethyl]-3,5-dimethyl-1H-pyrazol-4-yl]oxy]-5-chlorobenzonitrile 473923-93-2P, 3-[[5-(Bromomethyl)-1-[2-[[tert-butyldimethylsilyl]oxy]ethyl]-3-methyl-1H-pyrazol-4-yl]oxy]-5-chlorobenzonitrile 473923-94-3P, 3-[[5-(Aminomethyl)-1-[2-[[tert-butyldimethylsilyl]oxy]ethyl]-3-methyl-1H-pyrazol-4-yl]oxy]-5-chlorobenzonitrile 473924-12-8P, 3-[[1-[2-[[tert-Butyldimethylsilyl]oxy]ethyl]-3,5-diethyl-1H-pyrazol-4-yl]oxy]-5-fluorobenzonitrile 473924-13-9P, 3-[[3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-fluorobenzonitrile 473924-14-0P, 3-[[3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-fluorobenzamide 473924-15-1P, 3-[[3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-(1H-pyrazol-1-yl)benzonitrile 473924-17-3P, 5-[[3,5-Diethyl-1-[3-(tetrahydro-2H-pyran-2-yloxy)propyl]-1H-pyrazol-4-yl]oxy]isophthalonitrile 473924-18-4P, 3-[(1-Acetyl-3,5-dimethyl-1H-pyrazol-4-yl)oxy]-5-fluorobenzonitrile 473924-19-5P, 3-[[1-Acetyl-3-(bromomethyl)-5-methyl-1H-pyrazol-4-yl]oxy]-5-fluorobenzonitrile 473924-20-8P, 3-[[3,5-Diethyl-1-[2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-(1,2-dihydro-2-oxo-1-pyridyl)benzonitrile 473924-21-9P, 3-[[3,5-Diethyl-1-[2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-(1,6-dihydro-6-oxo-1,2-diazin-1-yl)benzonitrile 473924-22-0P, 3-[[3,5-Diethyl-1-[2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-(2,5-dihydro-2,3-dimethyl-5-oxo-1H-pyrazol-1-yl)benzonitrile 473924-23-1P, 3-[[3,5-Dimethyl-1-acetyl-1H-pyrazol-4-yl]oxy]-5-cyanobenzonitrile 473924-24-2P, 3-[[3,5-Dimethyl-1-acetyl-1H-pyrazol-4-yl]oxy]-5-methylbenzonitrile 473924-25-3P, 3-[[3,5-Dimethyl-1-acetyl-1H-pyrazol-4-yl]oxy]benzonitrile 473924-26-4P, 3-[[3-Bromomethyl-5-methyl-1-acetyl-1H-pyrazol-4-yl]oxy]-5-cyanobenzonitrile 473924-27-5P, 3-[[3-Bromomethyl-5-methyl-1-acetyl-1H-pyrazol-4-yl]oxy]-5-methylbenzonitrile 473924-28-6P, 3-[[3-Bromomethyl-5-methyl-1-acetyl-1H-pyrazol-4-yl]oxy]benzonitrile 473924-34-4P, 4-(3,5-Difluorophenoxy)-3,5-diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazole 473924-36-6P, 4-[3,5-Bis(1H-pyrazol-1-yl)phenoxy]-3,5-diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazole 473924-37-7P, 3,5-Diethyl-4-[3-fluoro-5-(1H-pyrazol-1-yl)phenoxy]-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazole 473924-38-8P, 3-[[3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-methoxybenzonitrile 473924-42-4P, 3-[[3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-

L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 473923-49-8 CAPLUS
CN 1H-Pyrazole, 1-acetyl-4-(3,5-dichlorophenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 473923-52-3 CAPLUS
CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3,5-dichlorophenoxy)-5-methyl- (9CI) (CA INDEX NAME)



RN 473923-61-4 CAPLUS
CN 3H-Pyrazol-3-one, 4-(3,5-dichlorophenoxy)-5-ethyl-2,4-dihydro-2-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 473923-63-6 CAPLUS
CN 3H-Pyrazol-3-one, 4-(3,5-dichlorophenoxy)-2-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-5-ethyl-2,4-dihydro- (9CI) (CA INDEX NAME)



RN 473923-65-8 CAPLUS
CN Methanesulfonic acid, trifluoro-, 4-(3,5-dichlorophenoxy)-1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3-ethyl-1H-pyrazol-5-yl ester (9CI) (CA INDEX NAME)



RN 473923-70-5 CAPLUS
CN 1H-Pyrazole, 1-acetyl-4-(3-chloro-5-cyanophenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)

RN 473923-85-2 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-5-methyl-3-(1-methylethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473923-89-6 CAPLUS
CN 1H-Pyrazole, 4-(3,5-dichlorophenoxy)-1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 473923-91-0 CAPLUS
CN 1H-Pyrazole, 5-(bromomethyl)-4-(3,5-dichlorophenoxy)-1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 473923-73-8 CAPLUS
CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3-chloro-5-cyanophenoxy)-5-methyl- (9CI) (CA INDEX NAME)



RN 473923-77-2 CAPLUS
CN 3-Pyridinemethanamine, N-[[4-(3,5-dichlorophenoxy)-1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3-methyl-1H-pyrazol-5-yl]methyl]- (9CI) (CA INDEX NAME)





RN 473923-92-1 CAPLUS
CN Benzonitrile, 3-chloro-5-[[1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3,5-dimethyl-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473923-93-2 CAPLUS
CN Benzonitrile, 3-[[5-(bromomethyl)-1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3-methyl-1H-pyrazol-4-yl]oxy]-5-chloro- (9CI) (CA INDEX NAME)



RN 473923-94-3 CAPLUS
CN Benzonitrile, 3-[[5-(aminomethyl)-1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3-methyl-1H-pyrazol-4-yl]oxy]-5-chloro- (9CI) (CA INDEX NAME)



RN 473924-12-8 CAPLUS
CN Benzonitrile, 3-[[1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3,5-diethyl-1H-pyrazol-4-yl]oxy]-5-fluoro- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 473924-15-1 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 473924-13-9 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-fluoro- (9CI) (CA INDEX NAME)



RN 473924-14-0 CAPLUS
CN Benzamide, 3-[[3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-fluoro- (9CI) (CA INDEX NAME)



RN 473924-17-3 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-diethyl-1-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473924-18-4 CAPLUS
CN 1H-Pyrazole, 1-acetyl-4-(3-cyano-5-fluorophenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 473924-19-5 CAPLUS
CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3-cyano-5-fluorophenoxy)-5-methyl- (9CI) (CA INDEX NAME)



RN 473924-20-8 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-(2-oxo-1(2H)-pyridinyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 473924-21-9 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-(6-oxo-1(6H)-pyridazinyl)- (9CI) (CA INDEX NAME)



RN 473924-22-0 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-(2,5-dihydro-2,3-dimethyl-5-oxo-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 473924-23-1 CAPLUS
CN 1H-Pyrazole, 1-acetyl-4-(3,5-dicyanophenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 473924-24-2 CAPLUS
CN 1H-Pyrazole, 1-acetyl-4-(3-cyano-5-methylphenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 473924-25-3 CAPLUS
CN 1H-Pyrazole, 1-acetyl-4-(3-cyanophenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 473924-26-4 CAPLUS
CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3,5-dicyanophenoxy)-5-methyl- (9CI) (CA INDEX NAME)



RN 473924-27-5 CAPLUS
CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3-cyano-5-methylphenoxy)-5-methyl- (9CI) (CA INDEX NAME)



RN 473924-28-6 CAPLUS
CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3-cyanophenoxy)-5-methyl- (9CI) (CA INDEX NAME)



RN 473924-34-4 CAPLUS
CN 1H-Pyrazole, 4-(3,5-difluorophenoxy)-3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 473924-36-6 CAPLUS
CN 1H-Pyrazole, 4-(3,5-di-1H-pyrazol-1-ylphenoxy)-3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 473924-37-7 CAPLUS
CN 1H-Pyrazole, 3,5-diethyl-4-[3-fluoro-5-(1H-pyrazol-1-yl)phenoxy]-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 473924-38-8 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-methoxy- (9CI) (CA INDEX NAME)



RN 473924-42-4 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-(methylthio)- (9CI) (CA INDEX NAME)



RN 473924-43-5 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-[2-(dimethylamino)ethoxy]- (9CI) (CA INDEX NAME)



RN 473924-44-6 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-[2-(methylamino)ethoxy]- (9CI) (CA INDEX NAME)



RN 473924-45-7 CAPLUS
CN Acetamide, 2-[3-cyano-5-[[3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]phenoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 473924-46-8 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



RN 473924-48-0 CAPLUS
CN Benzonitrile, 3-fluoro-5-[[5-methyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-3-(trifluoromethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473924-49-1 CAPLUS
CN Benzamide, 3-cyano-5-[[3,5-diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473924-50-4 CAPLUS
CN 1H-Pyrazole, 1-acetyl-4-(3,5-dicyanophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473924-51-5 CAPLUS
CN 1H-Pyrazole, 1-acetyl-3-(1-bromoethyl)-4-(3,5-dicyanophenoxy)-5-ethyl- (9CI) (CA INDEX NAME)



RN 473924-52-6 CAPLUS
CN 1,3-Benzenedicarbonitrile, 5-[[5-ethyl-3-(1-hydroxyethyl)-1-[2-

[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473924-53-7 CAPLUS
CN Benzenecarboximidamide, 3-cyano-5-[[3,5-diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl]oxy]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 473924-54-8 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



RN 473924-55-9 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-(5-methyl-1,2,4-oxadiazol-3-yl)- (9CI) (CA INDEX NAME)



RN 473924-56-0 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-(5-ethyl-1,2,4-oxadiazol-3-yl)- (9CI) (CA INDEX NAME)



RN 473924-57-1 CAPLUS
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2001:915238 CAPLUS
DOCUMENT NUMBER: 136:200148
TITLE: Screening mixtures: an experiment in pesticide lead generation
AUTHOR(S): Fisher, Karl J.; Felix, Ray A.; Oliver, Robert M.
CORPORATE SOURCE: Zeneca Agrochemicals, Richmond, CA, 94804, USA
SOURCE: ACS Symposium Series (2002), 800(Synthesis and Chemistry of Agrochemicals VI), 9-15
CODEN: ACSMC8; ISSN: 0097-6156
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB Combinatorial libraries of potential herbicidal compds. were prepared by treatment of mixts. of 10 alkyl halides with heterocyclic nucleophiles; the products were then assayed for herbicidal activity. The screening of mixts. was evaluated as a way of improving the rate of new lead generation, one of the greatest challenges facing modern agricultural chemists. Herbicidal activity found in assays of the library compds. was linked in all cases either to a single compound from the mixture or to cumulative effects of multiple active compds. in a mixture The active compds. were prepared by individual synthesis upon deconvolution. The libraries led to various herbicidal compds., among which was triazolylthiobutyramide I, an active herbicide with a novel mode of action.

IT **401519-80-0P 401519-81-1P 401519-82-2P 401519-83-3P**
RL: AGR (Agricultural use); CPN (Combinatorial preparation); SPN (Synthetic preparation); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(preparation of combinatorial libraries of herbicidal compds. by nucleophilic substitution of alkyl halides with heterocyclic nucleophiles and active herbicidal compds. found in the libraries)

RN 401519-80-0 CAPLUS
CN 1H-Pyrazole-1-acetic acid, 4-(4-chlorophenoxy)-, ethyl ester (9CI) (CA INDEX NAME)



RN 401519-81-1 CAPLUS
CN 1H-Pyrazole-1-hexanoic acid, 4-(4-chlorophenoxy)-, ethyl ester (9CI) (CA INDEX NAME)



RN 401519-82-2 CAPLUS
CN 1H-Pyrazole-1-acetic acid, 4-(4-chlorophenoxy)-α-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 401519-83-3 CAPLUS
CN 1H-Pyrazole-1-pentanoic acid, 4-(4-chlorophenoxy)-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:631412 CAPLUS
DOCUMENT NUMBER: 131:243266
TITLE: Preparation of pyrazolyloximinoacetates and related compounds as agrochemical and industrial fungicides.
INVENTOR(S): Hirohara, Yoji; Sugano, Shigeyoshi; Nakashima, Hideki; Kimura, Takuo; Sakakibara, Takashi
PATENT ASSIGNEE(S): SDS Biotech K.K., Japan
SOURCE: Eur. Pat. Appl., 70 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 945437	A1	19990929	EP 1998-105673	19980327
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRIORITY APPLN. INFO.:			EP 1998-105673	19980327
OTHER SOURCE(S):	MARPAT 131:243266			

GI



AB Title compds. [I; X = CO2R1, CONHR1, CON(R1)2, cyano, 5-6 membered heteroaryl; Y = CH, N; W = alkylene, NR1, O; n = 0, 1; R = alkyl, haloalkyl; A, B, D = H, halo, R1, R1O, R1S, R1SO, R1SO2, (R1)2N, R102C, R1OR2, R1ON:CH, cyano, NO2, alkenyl, alkynyl, cycloalkyl, (substituted) Ph, PhCH2, PhO, PhCH2O, PhOR2, PhS, PhCH2S, PhSR2, PhCH2ON:CH, naphthyl, heteroaryl; R1 = alkyl, haloalkyl; R2 = alkylene; provided that A, B, D do not all = H and >2 of A, B, D do not = aryl or heteroaryl], were prepared Thus, Me 2-[3-methyl-5-(4-chlorophenyl)pyrazol-1-yl]-2-hydroxyiminoacetate (preparation given) was stirred with Me2SO4 and K2CO3 in DMF to give 82% Me 2-[3-methyl-5-(4-chlorophenyl)pyrazol-1-yl]-2-methoxyiminoacetate. The latter at 500 ppm gave 100% prevention of Pseudoperonospora cubensis on cucumbers.

IT 244270-51-7P 244270-52-8P 244270-53-9P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolyloximinoacetates and related compds. as agrochem. and industrial fungicides)

RN 244270-51-7 CAPLUS
CN 1H-Pyrazole-1-acetic acid, α-(methoxymethylene)-3-methyl-4-phenoxy-, methyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244270-52-8 CAPLUS
CN 1H-Pyrazole-1-acetamide, α-(methoxymethylene)-N,3-dimethyl-4-(3-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 244270-53-9 CAPLUS
CN 1H-Pyrazole-1-acetic acid, α-(methoxymethylene)-3-methyl-4-(3-methylphenoxy)-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:572284 CAPLUS
DOCUMENT NUMBER: 129:212968
TITLE: Preparation of N-aryl-3-aryl-4-substituted-4,5-dihydro-1H-pyrazole-1-carboxamides as insecticides
INVENTOR(S): Jacobson, Richard Martin
PATENT ASSIGNEE(S): Rohm and Haas Co., USA
SOURCE: U.S., 49 pp., Cont.-in-part of U.S. Ser. No. 415,117, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5798311	A	19980825	US 1995-468284	19950606
ZA 9105394	A	19920325	ZA 1991-5394	19910711
PRIORITY APPLN. INFO.:			US 1990-553220	B2 19900713
			US 1991-713692	B3 19910617
			US 1993-49891	B1 19930419
			US 1995-415117	B2 19950329
OTHER SOURCE(S):	MARPAT 129:212968			

GI



AB The N-aryl-3-aryl-4-substituted-4,5-dihydro-1H-pyrazole-1-carboxamides I [R, R1 = H, halo, (halo)alkyl, (halo)alkoxy, nitro, etc.; R2 = H, halo, haloalkyl or haloalkoxy; R3 = halo, haloalkyl or haloalkoxy; V = H, alkyl, alkylcarbonyl, alkoxycarbonyl or formyl; Y1 = H, alkyl, alkenyl, alkynyl, (halo)phenyl, etc.; Y2 = H, alkyl, alkoxycarbonyl, cyano, etc.] and I salts are prepared as insecticides.

IT 141128-27-0P 141128-28-1P
RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation as insecticide)

RN 141128-27-0 CAPLUS
CN 1H-Pyrazole-1-carboxamide, 3-(4-chlorophenyl)-4,5-dihydro-4-phenoxy-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 141128-28-1 CAPLUS
CN 1H-Pyrazole-1-carboxamide, 4-(4-chlorophenoxy)-3-(4-chlorophenyl)-4,5-dihydro-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:411990 CAPLUS
DOCUMENT NUMBER: 127:81368
TITLE: Synthesis of some new oximes, thiocarbamates, pyrazolyloxy, isoxazolyloxy, pyrimidyloxy and pyridyloxy quinolines
AUTHOR(S): Abdel Hafez, Ali A.
CORPORATE SOURCE: Chem. Dep., Fac. Sci., Assiut Univ., Assiut, Egypt
SOURCE: Qatar University Science Journal (1994), 14(Spec. Issue), 108-113
CODEN: QUSJEV; ISSN: 1023-8948
PUBLISHER: University of Qatar, Faculty of Science
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The reaction of I or its corresponding chalcones with hydroxylamine in boiling pyridine gave oximes in almost quant. yield. Reaction of the oximes with Ph isothiocyanate gave the corresponding thiocarbamates. A new series of pyrazolyloxy-, isoxazolyloxy-, pyrimidyloxy-, and pyridyloxy-substitute quinolines were obtained. The in vitro antibacterial and antifungal activity were screened for all the compds. prepared; some of the compds. tested showed interesting results.

IT 191873-96-8P 191873-97-9P 191873-98-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, bactericidal, and fungicidal activity of (morpholinosulfonyl)quinolines)

RN 191873-96-8 CAPLUS
CN 1H-Pyrazole, 1-acetyl-4,5-dihydro-3-(4-morpholinyl)-4-[[5-(4-morpholinylsulfonyl)-8-quinolinyl]oxy]-5-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 191873-97-9 CAPLUS
CN 1H-Pyrazole, 1-acetyl-4,5-dihydro-5-(4-methoxyphenyl)-3-(4-morpholinyl)-4-[[5-(4-morpholinylsulfonyl)-8-quinolinyl]oxy]- (9CI) (CA INDEX NAME)



RN 191873-98-0 CAPLUS
CN 1H-Pyrazole, 1-acetyl-4,5-dihydro-3-(4-morpholinyl)-4-[[5-(4-morpholinylsulfonyl)-8-quinolinyl]oxy]-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:262919 CAPLUS
DOCUMENT NUMBER: 127:5038
TITLE: Synthesis, reaction, theoretical calculation, NMR study and x-ray crystal structure of 1-substituted and 1-unsubstituted 1H-pyrazol-5(2H)-ones
AUTHOR(S): Attanasi, Orazio A.; De Crescentini, Lucia; Filippone, Paolino; Foresti, Elisabetta; Galeazzi, Roberta; Ghiviriga, Ion; Katritzky, Alan R.
CORPORATE SOURCE: Facolta Scienze, Univ. Urbino, Urbino, 61029, Italy
SOURCE: Tetrahedron (1997), 53(15), 5617-5640
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB 1-Substituted 4-alkoxy-, 4-alkylthio-, and 4-aryloxy-1H-pyrazol-5(2H)-ones have been prepared by the reaction of conjugated azoalkenes with alcs., thiols, and phenols. In some cases the intermediate hydrazones were isolated, while in others the products were obtained in one step. 1-Unsubstituted 4-alkoxy-, 4-alkylthio-, and 4-aryloxy-1H-pyrazol-5(2H)-ones were produced by methanolysis of the corresponding 1-substituted derivs. under reflux. Some of these compds. were studied by mol. mechanics calcns., as well as deuterium induced shifts (DIS) on 13C chemical shifts, and tentative conclusion was drawn about their tautomerism and conformations. X-Ray crystal structure detns. of 1-(aminocarbonyl)-3-methyl-4-methoxy-1H-pyrazol-5(2H)-one and 3-methyl-4-methoxy-1H-pyrazol-5(2H)-one demonstrated that both mols. exist in the crystal exclusively in the HN-CO tautomeric form. Some previously reported structural assignments in some pyrazolones and hydroxypyrazoles were corrected

IT 190257-08-0P 190257-09-1P 190257-14-8P
190257-15-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis, reaction, theor. calcn., NMR study and x-ray crystal structure of 1H-pyrazol-5(2H)-ones)

RN 190257-08-0 CAPLUS
CN 1H-Pyrazole-1-carboxamide, 2,5-dihydro-3-methyl-4-(4-nitrophenoxy)-5-oxo- (9CI) (CA INDEX NAME)



RN 190257-09-1 CAPLUS
CN 1H-Pyrazole-1-carboxamide, 2,5-dihydro-3-methyl-4-(4-nitrophenoxy)-5-oxo-N-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 190257-14-8 CAPLUS
CN 1H-Pyrazole-1-carboxamide, 2,5-dihydro-3-methyl-5-oxo-4-phenoxy- (9CI) (CA INDEX NAME)



RN 190257-15-9 CAPLUS
CN 1H-Pyrazole-1-carboxamide, 2,5-dihydro-3-methyl-5-oxo-4-phenoxy-N-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 92 THERE ARE 92 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:35296 CAPLUS
DOCUMENT NUMBER: 124:90281
TITLE: Preparation of 1H-imidazo[1,2-b]pyrazole derivatives
INVENTOR(S): Sato, Tadahisa; Matsuoka, Mitsuyuki
PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07278455	A2	19951024	JP 1994-68738	19940406

PRIORITY APPLN. INFO.: JP 1994-68738 19940406
OTHER SOURCE(S): MARPAT 124:90281
GI



AB The title compds. I (R1-2 = H, substituent; R3 = H, halo, alkoxy, etc.; R4 = alkyl, aryl; n = 0-2), useful as starting materials for color photog. couplers and dyes, are prepared from 5-amino-1H-pyrazole derivs. Acylating 5-amino-4-chloro-3-methyl-1H-pyrazole with BrCH2COPh in the presence of γ-collidine, reacting the product with PhSSPh in the presence of NaH, and heating at 60° in the presence of HCl gave I (R1 = Me; R2, R4 = Ph; R3 = Cl; n = 0).

IT 172887-69-3P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization of)

RN 172887-69-3 CAPLUS
CN Ethanone, 2-[5-amino-3-methyl-4-(4-methylphenoxy)-1H-pyrazol-1-yl]-1-phenyl-2-(phenylthio)- (9CI) (CA INDEX NAME)

L6 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 172887-64-8P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction with di-Ph disulfide)

RN 172887-64-8 CAPLUS
CN Ethanone, 2-[5-amino-3-methyl-4-(4-methylphenoxy)-1H-pyrazol-1-yl]-1-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:677721 CAPLUS
DOCUMENT NUMBER: 123:183352
TITLE: Silver halide color photographic materials containing timing DIR-couplers
INVENTOR(S): Sugino, Motoaki; Asatake, Atsushi; Kaneko, Yutaka
PATENT ASSIGNEE(S): Konishiroku Photo Ind, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07084348	A2	19950331	JP 1993-229118	19930914
PRIORITY APPLN. INFO.:			JP 1993-229118	19930914

OTHER SOURCE(S): MARPAT 123:183352
GI



I

AB The photog. materials with Ag halide emulsions on supports contain I (R, R1 = H, substituent or ring atom; DI = development inhibitor; TIME = timing group which retards the DI-releasing process; n = 0-2); the development inhibitor is released by reaction with the oxidized developing agent. Image sharpness and storage stability are improved.

IT 167381-31-9 167381-35-3 167381-36-4
RL: TEM (Technical or engineered material use); USES (Uses)
(pyrazolidone photog. development inhibitor-releasing coupler)

RN 167381-31-9 CAPLUS
CN 1-Pyrazolidineacetic acid, 4-[4-[[[5-amino-4-(2-propenyl)-4H-1,2,4-triazol-3-yl]thio]methyl]-2-[(methylsulfonyl)amino]phenoxy]-3,5-dioxo-2-(2,4,6-trichlorophenyl)-, 1-[(decyloxy)carbonyl]pentyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 167381-35-3 CAPLUS
CN 1-Pyrazolidinecarboxylic acid, 4-[4-[(3-carboxy-1-oxopropyl)amino]-2-[[(4,5,6,7-tetrahydro-2-benzothiazolyl)thio]methyl]phenoxy]-3,5-dioxo-2-phenyl-, 1-[2-oxo-2-(tetradecyloxy)ethyl] ester (9CI) (CA INDEX NAME)



RN 167381-36-4 CAPLUS
CN 3,5-Pyrazolidinedione, 1-acetyl-4-[2-nitro-4-[1-[(1-phenyl-1H-tetrazol-5-yl)thio]undecyl]phenoxy]-2-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:547587 CAPLUS
DOCUMENT NUMBER: 123:44276
TITLE: Photographic magenta coupler having dioxopyrazolidine nucleus
INVENTOR(S): Sugino, Motoaki; Asatake, Atsushi; Kaneko, Yutaka
PATENT ASSIGNEE(S): Konishiroku Photo Ind, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 31 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07036159	A2	19950207	JP 1993-179283	19930720
JP 3208694	B2	20010917		
PRIORITY APPLN. INFO.:			JP 1993-179283	19930720

OTHER SOURCE(S): MARPAT 123:44276
GI



I

AB The coupler has a structure I (R1, R2 = H, substituent; R1 and R2 may form a ring; X = H, leaving group released by the coupling reaction with the developer oxidant). The magenta coupler giving a dye with an excellent stability to light, heat, and humidity.

IT 163970-11-4 163970-15-8 163970-18-1
163970-19-2
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. magenta coupler having dioxopyrazolidine nucleus)

RN 163970-11-4 CAPLUS
CN 1-Pyrazolidineacetic acid, α-(1,1-dimethylethyl)-4-(2-methylphenoxy)-3,5-dioxo-2-phenyl-, decyl ester (9CI) (CA INDEX NAME)



RN 163970-15-8 CAPLUS
CN 3,5-Pyrazolidinedione, 4-(4-nitrophenoxy)-1-(1-oxotridecyl)-2-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 163970-18-1 CAPLUS
CN 3,5-Pyrazolidinedione, 1-(1-ethyloctyl)-2-(2-methoxyethyl)-4-(2-nitrophenoxy)- (9CI) (CA INDEX NAME)



RN 163970-19-2 CAPLUS
CN 1-Pyrazolidineacetic acid, 2-[2-(hexadecylamino)-2-oxoethyl]-4-[4-[(1-methylethoxy)carbonyl]phenoxy]-3,5-dioxo-, methyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L6 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1992:214493 CAPLUS
DOCUMENT NUMBER: 116:214493
TITLE: Preparation of N-aryl-3-aryl-4-substituted-4,5-dihydro-1H-pyrazole-1-carboxamides as pesticides
INVENTOR(S): Jacobson, Richard Martin
PATENT ASSIGNEE(S): Rohm and Haas Co., USA
SOURCE: Eur. Pat. Appl., 84 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 466408	A1	19920115	EP 1991-306113	19910704
EP 466408	B1	20000112		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 188690	E	20000115	AT 1991-306113	19910704
ES 2143459	T3	20000516	ES 1991-306113	19910704
CA 2046420	AA	19920114	CA 1991-2046420	19910705
AU 9180313	A1	19920116	AU 1991-80313	19910710
AU 652762	B2	19940908		
ZA 9105394	A	19920325	ZA 1991-5394	19910711
BR 9102980	A	19920211	BR 1991-2980	19910712
HU 58702	A2	19920330	HU 1991-2355	19910712
JP 06080642	A2	19940322	JP 1991-172304	19910712
JP 3321186	B2	20020903		
AU 9480323	A1	19950413	AU 1994-80323	19941208
AU 680315	B2	19970724		

PRIORITY APPLN. INFO.: US 1990-553220 A 19900713
US 1991-713692 A 19910617

OTHER SOURCE(S): MARPAT 116:214493
GI



I II

AB Title compds. [I; A = (hetero)aryl; Y = isothiocyanato, isocyano, amino, alkanoyloxy, alkoxy, PhO, alkylthio, phenylthio; Z = H, alkyl; B = (hetero)aryl; U = O, S; V = H, alkyl, alkoxyalkyl, alkylthioalkyl, CHO, alkylcarbonyl, CO2H, PhO, alkoxycarbonyloxy, alkylsulfonyl, PhS, etc.], were prepared Thus, N-(4-trifluoromethylphenyl)-3-(4-chlorophenyl)-4-carbomethoxy-4-methyl-4,5-dihydro-1H-pyrazole-1-carboxamide was converted successively to the 4-acid, 4-carbonyl chloride, 4-azidocarbonyl derivative, 4-isocyanato derivative and finally to title carboxamide II. II at 600 ppm sprays gave complete control of Epilachna varivestis, Spodoptera eridonia,

L6 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
and Anthonomus gradis grandis.

IT 141128-27-0P 141128-28-1P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as pesticide)

RN 141128-27-0 CAPLUS
CN 1H-Pyrazole-1-carboxamide, 3-(4-chlorophenyl)-4,5-dihydro-4-phenoxy-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 141128-28-1 CAPLUS
CN 1H-Pyrazole-1-carboxamide, 4-(4-chlorophenoxy)-3-(4-chlorophenyl)-4,5-dihydro-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1977:535318 CAPLUS
DOCUMENT NUMBER: 87:135318
TITLE: 3,4-Disubstituted 2-(β-naphthyloxy)ethylpyrazolones
INVENTOR(S): Moeller, Eike; Meng, Karl; Seuter, Friedel; Horstmann, Harald
PATENT ASSIGNEE(S): Bayer A.-G., Fed. Rep. Ger.
SOURCE: Ger. Offen., 49 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2554701	A1	19770609	DE 1975-2554701	19751205
SE 7613536	A	19770606	SE 1976-13536	19761202
NL 7613451	A	19770607	NL 1976-13451	19761202
BE 849047	A1	19770603	BE 1976-172954	19761203
DK 7605456	A	19770606	DK 1976-5456	19761203
JP 52071467	A2	19770614	JP 1976-144842	19761203
FR 2333505	A1	19770701	FR 1976-36543	19761203
ES 453908	A1	19771116	ES 1976-453908	19761203

PRIORITY APPLN. INFO.: DE 1975-2554701 A 19751205
GI



I

AB Title compds. I (R = Me, R1 = Et, Bu, hexyl, CH2CH2OEt, Ph, CH2CH2OPh, SCF3, OPh, R = Et, R1 = Me, R2 = H, Br) were prepared by condensing 2-(2-naphthyloxy)ethylhydrazines with RCOCHR1CO2Et. I (R = Me, R1 = hexyl, R2 = H) at 10 mg caused 51% inhibition of thrombus formation in rats.

IT 64076-70-6P 64076-73-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 64076-70-6 CAPLUS
CN 3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-[2-(2-naphthalenyloxy)ethyl]-4-phenoxy- (9CI) (CA INDEX NAME)



RN 64076-73-9 CAPLUS
CN 3H-Pyrazol-3-one, 2-[2-[(5-bromo-2-naphthalenyl)oxy]ethyl]-2,4-dihydro-5-methyl-4-phenoxy- (9CI) (CA INDEX NAME)

L6 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L6 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1974:403821 CAPLUS
DOCUMENT NUMBER: 81:3821
TITLE: Phosgene immonium salts. XIII. Dichloromalonyl cyanines and 3,5-bis(dimethylamino)pyrazoles
AUTHOR(S): De Voghel, Guy J.; Eggerichs, Terry L.; Janousek, Zdenek; Viehe, Heinz G.
CORPORATE SOURCE: Lab. Chim. Org., Univ. Louvain, Louvain-la-Neuve, Belg.
SOURCE: Journal of Organic Chemistry (1974), 39(9), 1233-5 CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB The chloromalonyl cyanine derivs. (I,R = alkyl, aryl, halo, alkoxy) were synthesized by the reaction of RCH2CONMe2 with Cl2C:N+Me2 Cl-. The biselectrophilic system in I is of general applicability to the synthesis of aminated heterocyclic systems. I reacts with hydrazines NH2NHR1 (R1 = Me, Ph, PhSO2 etc.) to give 3,5-bis(dimethylamino)pyrazoles, II.
IT 50860-18-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 50860-18-9 CAPLUS
CN 1H-Pyrazole-1-carboxylic acid, 3,5-bis(dimethylamino)-4-phenoxy-, ethyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1972:488382 CAPLUS
DOCUMENT NUMBER: 77:88382
TITLE: 1-Phenyl-2-acyl-3-amino-2-pyrazolin-5-ones from 1-phenyl 3-azidocarbonyl-2-pyrazolin-5-ones
AUTHOR(S): Hendess, Raymond W.
CORPORATE SOURCE: Res. Lab., Eastman Kodak Co., Rochester, NY, USA
SOURCE: Journal of Organic Chemistry (1972), 37(15), 2400-1 CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 77:88382
AB The Curtius reaction of 1-phenyl-3-azidocarbonyl-2-pyrazolin-5-one in HOAc leads to 1-phenyl-2-acetyl-3-amino-3-pyrazolin-5-one rather than the expected 1-phenyl-3-acetamido-2-pyrazolin-5-one.
IT 34804-14-3P 34804-15-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 34804-14-3 CAPLUS
CN 3H-Pyrazol-3-one, 1-acetyl-5-amino-1,2-dihydro-4-phenoxy-2-phenyl- (9CI) (CA INDEX NAME)



RN 34804-15-4 CAPLUS
CN 3H-Pyrazol-3-one, 1-acetyl-5-amino-1,2-dihydro-4-(4-methylphenoxy)-2-phenyl- (9CI) (CA INDEX NAME)



=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	92.07	282.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-13.14	-13.14

FILE 'REGISTRY' ENTERED AT 13:51:25 ON 08 APR 2005

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 APR 2005 HIGHEST RN 848122-48-5
DICTIONARY FILE UPDATES: 7 APR 2005 HIGHEST RN 848122-48-5

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *



chain nodes :
6 14 15 16 17 18 19
ring nodes :
1 2 3 4 5 7 8 9 10 11 12
chain bonds :
2-14 3-6 5-17 6-7 17-18 18-19
ring bonds :
1-2 1-5 2-3 3-4 4-5 7-8 7-12 8-9 9-10 10-11 11-12



Structure attributes must be viewed using STN Express query preparation.

=> d his

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	43.51	326.50

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-13.14

FILE 'CAPLUS' ENTERED AT 13:52:19 ON 08 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 8 Apr 2005 VOL 142 ISS 16
FILE LAST UPDATED: 7 Apr 2005 (20050407/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l6 and l9
                2 L9
L11             2 L6 AND L9

=> d ibib l11 1-2
```

L11 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:253142 CAPLUS
DOCUMENT NUMBER: 140:287377
TITLE: Preparation of pyrazolyloxyisophthalonitrile as reverse transcriptase inhibitor in the treatment of AIDS
INVENTOR(S): Mowbary, Charles Eric; Price, David Anthony; Selby, Matthew Duncan; Stupple, Paul Anthony
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004024147	A1	20040325	WO 2003-IB3946	20030908
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004132793	A1	20040708	US 2003-661947	20030912
PRIORITY APPLN. INFO.:			GB 2002-21477 A	20020916
			GB 2002-23354 A	20021008
			US 2002-433397P P	20021213

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:832763 CAPLUS
DOCUMENT NUMBER: 137:337884
TITLE: Preparation of aryloxy pyrazole derivatives as reverse transcriptase inhibitors for treating HIV
INVENTOR(S): Jones, Lyn Howard; Mowbray, Charles Eric; Price, Davis Anthony; Selby, Matthew Duncan; Stupple, Paul Anthony
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 306 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085860	A1	20021031	WO 2002-IB1234	20020404
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2443449	AA	20021031	CA 2002-2443449	20020404
EP 1377556	A1	20040107	EP 2002-708600	20020404
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300497	A	20040216	EE 2003-497	20020404
BR 2002008811	A	20040309	BR 2002-8811	20020404
JP 2004531535	T2	20041014	JP 2002-583387	20020404
US 2003100554	A1	20030529	US 2002-118512	20020405
ZA 2003007095	A	20040910	ZA 2003-7095	20030910
NO 2003004523	A	20031209	NO 2003-4523	20031009
PRIORITY APPLN. INFO.:			GB 2001-8999 A	20010410
			GB 2001-27426 A	20011115
			US 2001-289570P P	20010508
			US 2002-346727P P	20020107
			WO 2002-IB1234 W	20020404

OTHER SOURCE(S): MARPAT 137:337884
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.10	329.60

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-13.14

STN INTERNATIONAL LOGOFF AT 13:53:37 ON 08 APR 2005